Abstract:OBJECTIVE:To investigate the effectiveness, safety, and tolerability of moxifloxacin (MXF) (intravenous [IV] or sequential therapy [IV followed by oral]) under daily treatment conditions in a large number of patients with respiratory tract infections.DESIGN:Patients with a diagnosis of respiratory tract infection should be treated with MXF IV and/or tablets 400 mg once daily for a duration at the physician's discretion. For each patient, the physician documented data at an initial visit and at the end of therapy (EOT) visit and/or, in the case of sequential therapy, an interim visit when the patient switched to oral treatment.RESULTS:A total of 1953 patients treated with MXF were documented and were valid for an effectiveness and safety evaluation. An improvement was observed in 98.1% (n = 1911/1949) of patients treated with MXF. Recovery was documented in 89.9% (n = 1754/1951) of the patients. At the EOT visit, severity of infection was assessed to be "relieved" or at least "improved" in 96.5% (n = 1873/1940) of the patients. Physicians assessed overall effectiveness as "good" or "very good" in 93.3% (n = 1822/1953) of all patients. The physicians' overall tolerability rating was "very good" or "good" in 93.5% (n = 1827/1953) of all patients. The incidence rates of adverse events (AEs) and adverse drug reactions (ADRs) were 0.72% (n = 14) and 0.67% (n = 13), respectively. One serious AE "falling white blood cell count" occurred (0.05%), which was also defined as a serious ADR and resolved.CONCLUSION:MXF was generally well tolerated and highly effective in the treatment of different respiratory tract infections. The incidence of AEs and ADRs was low. The efficacy, safety, and tolerability information collected in this study confirms the clinical safety profile of MXF and its value as antibiotic treatment for respiratory tract infections.

Clinical efficacy of moxifloxacin injection on lower respiratory tract infections

Randomized Controlled Clinical Trial of Moxifloxacin Versus Levofloxacin Injection in the Treatment of Community Acquired Pneumonia

A randomized multicenter clinical study of injectable levofloxacin in the treatment of acute bacterial infections

A clinical randomized controlled trial of pazufloxacin injection in treatment of bacterial infection in 111 patients

Clinical Efficacy of Moxifloxacin in the Treatment of Anaerobic Infection

Clinical randomized controlled trials of Gatifloxacin injection in the treatment of bacterial infections of lower respiratory tract and urinary tract

Clinical Randomized Controlled Trials of Gatifloxacin Injection in Treatment of Bacterial Infections of Respiratory Tract

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

Double-blind Randomized Controlled Clinical Trial on Gatifloxacin Versus Levofloxacin Injection for Treating Acute Bacterial Infections

Clinical study of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia

Observation on clinical effects of intravenous levofloxacin 500 mg once-daily vs 300 mg twice-daily in the treatment of lower respiratory tract bacterial infections

Comprehensive clinical evaluation of moxifloxacin: A retrospective study

A Randomized Double-blind Control Clinical Study on Moxifloxacin for Treatment of Bacterial Skin Infections

A Randomized,controlled Clinical Trial of Levofloxacin Versus Ceftriaxone and Azithromycin in the Treatment of Community-Acquired Lower Respiratory Tract Infections

Efficacy and Safety of Intravenous Moxifloxacin Versus Cefoperazone with Azithromycin in the Treatment of Community Acquired Pneumonia

The Therapeutic Effect of Pazufloxacin Mesilate on Acute Respiratory Infection of the Elderly

Intravenous Moxifloxacin in Routine Hospital Treatment of Respiratory Tract Infections in China: Results of a Multicenter, Noninterventional Study.

Phamacodynamics and pharmacokinetics of levofloxacin in patients with lower respiratory tract infection

Randomized Controlled Study on Gatifloxacin and Levofloxacin Injection in the Treatment of Acute Gonococcal Urinary and Reproductive Tract Infections

Clinical Study of Inhaled Ambroxol in the Adjunctive Treatment of Lower Respiratory Tract Infection Induced by Pseudomonas Aeruginosa

Clinical Comparative Study of Injectable Azithromycin and Cefuroxime in the Treatment of Lower Respiratory Tract Infection